Skip to main content
. 2018 Dec 14;24(46):5288–5296. doi: 10.3748/wjg.v24.i46.5288

Table 3.

Comparative of maintenance of remission at 12 mo in patients with initial remission in both groups

Infliximab original group 95%CI CT-P13 group 95%CI P value Rate Difference (95%CI)
Maintained basal remission at 12 mo 62/74 (83.7%) 74.7-92.9 54/74 (72.9%) 62.2-83.5 0.162 -0.037-0.253
Maintained basal remission at 12 mo CD 42/51 (82.3%) 70.9-93.8 37/53 (69.8%) 56.5-83.1 0.205 -0.056-0.307
Maintained basal remission at 12 mo UC 20/23 (87%) 66.4-97.2 17/21 (81.0%) 62.5-92.5 0.890 -0.203-0.23

CD: Crohn's disease; UC: Ulcerative colitis.